Ignite Creation Date:
2025-12-24 @ 3:02 PM
Ignite Modification Date:
2026-01-04 @ 10:51 AM
Study NCT ID:
NCT00247559
Status:
COMPLETED
Last Update Posted:
2019-11-22
First Post:
2005-11-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D019274', 'term': 'Botulinum Toxins, Type A'}, {'id': 'C542869', 'term': 'abobotulinumtoxinA'}], 'ancestors': [{'id': 'D001905', 'term': 'Botulinum Toxins'}, {'id': 'D008666', 'term': 'Metalloendopeptidases'}, {'id': 'D010450', 'term': 'Endopeptidases'}, {'id': 'D010447', 'term': 'Peptide Hydrolases'}, {'id': 'D006867', 'term': 'Hydrolases'}, {'id': 'D004798', 'term': 'Enzymes'}, {'id': 'D045762', 'term': 'Enzymes and Coenzymes'}, {'id': 'D045726', 'term': 'Metalloproteases'}, {'id': 'D001426', 'term': 'Bacterial Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D001427', 'term': 'Bacterial Toxins'}, {'id': 'D014118', 'term': 'Toxins, Biological'}, {'id': 'D001685', 'term': 'Biological Factors'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 221}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2004-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-11', 'completionDateStruct': {'date': '2005-04-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-11-21', 'studyFirstSubmitDate': '2005-11-01', 'studyFirstSubmitQcDate': '2005-11-01', 'lastUpdatePostDateStruct': {'date': '2019-11-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2005-11-02', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2005-04-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "Change in severity of crow's feet at maximum smile at week 4, compared to baseline, assessed photographically by independent panel"}], 'secondaryOutcomes': [{'measure': "At week 2,4,8,12,16,20,24, compared to baseline: change in severity of crow's feet at rest & max. smile, assessed by investigator & independent panel (photographically); change in patient satisfaction with appearance of crow's feet & general appearance"}]}, 'conditionsModule': {'keywords': ["crow's feet", 'cosmesis', 'ageing'], 'conditions': ['Lateral Canthal Lines']}, 'descriptionModule': {'briefSummary': 'Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin (BoNT-A), and the widespread use of the BoNT-A for cosmetic applications, the number of randomised, controlled clinical trials is small. Much of the published information is based on open-label studies or anecdotal data. Of the robust trial data that is available, the vast majority relates to the treatment of glabellar lines, and there is little data available regarding the use of BoNT-A in lateral canthal lines. This study aims to determine the optimum dose for the use of BoNT-A in this area.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male or female patients, 18 to 65 years of age.\n* In the opinion of the Investigator moderate to severe lateral canthal lines (crow's feet) during maximum smile on both sides of the face.\n* In the opinion of the Investigator mild to severe lateral canthal lines (crow's feet) at rest on both sides of the face.\n\nExclusion Criteria:\n\n* Any prior surgery affecting the orbicularis oculi muscle, prior blepharoplasty or brow lift, or any prior cosmetic procedures or scars that may interfere with the evaluation of the study results.\n* Previous insertion of any non-absorbable material in the periorbital region or facial treatment with augmentation material within 12 months prior to screening.\n* Any prior treatment with botulinum toxin (of any serotype).\n* Previous treatment with lasers for skin resurfacing or treatment with deep chemical peels within 12 months prior to screening.\n* Inability to substantially lessen the lateral canthal lines by physically spreading them apart.\n* Facial conditions that could affect safety or efficacy results such as: active infection or other skin problem in the periorbital area (e.g. acute acne lesions or ulcers); history of facial nerve palsy; marked facial asymmetry; ptosis; excessive dermatochalasis; deep dermal scarring; thick sebaceous skin; photodamage etc."}, 'identificationModule': {'nctId': 'NCT00247559', 'briefTitle': "Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)", 'organization': {'class': 'INDUSTRY', 'fullName': 'Ipsen'}, 'officialTitle': "A Phase II, Multi-Centre, Randomised, Double-blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15, 30 or 45 Units (Per Eye) of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow's Feet)", 'orgStudyIdInfo': {'id': 'Y-97-52120-723'}, 'secondaryIdInfos': [{'id': '2004-001421-17', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'Botulinum toxin type A', 'type': 'BIOLOGICAL', 'otherNames': ['AbobotulinumtoxinA (Dysport®)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '33200', 'city': 'Bordeaux', 'country': 'France', 'facility': 'Clinique Bel Air', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '06002', 'city': 'Nice', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Nice', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'zip': '92211', 'city': 'Saint-Cloud', 'country': 'France', 'facility': 'Service de Chirurgie Maxillo Faciale', 'geoPoint': {'lat': 48.84598, 'lon': 2.20289}}, {'zip': '10117', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite-Universitatsmedizin Berlin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '01067', 'city': 'Dresden', 'country': 'Germany', 'facility': 'Dermatologie, Stadt. Klinikum Dresden-Friedrichstadt', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '66421', 'city': 'Homburg', 'country': 'Germany', 'facility': 'Universitats - Hautklinik', 'geoPoint': {'lat': 49.32637, 'lon': 7.33867}}, {'zip': 'SG8 5QD', 'city': 'Cambridge', 'state': 'England', 'country': 'United Kingdom', 'facility': 'The Cambridge Private Hospital', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'W1G 7LE', 'city': 'London', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Harley Street', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'G81 4HX', 'city': 'Clydebank', 'state': 'Scotland', 'country': 'United Kingdom', 'facility': 'The Golden Jubilee National Hospital', 'geoPoint': {'lat': 55.90137, 'lon': -4.4057}}], 'overallOfficials': [{'name': 'UK Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Ipsen'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Ipsen', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}